With over 30 years-experience in the Pharmaceutical/Biopharm Industry, Annette Clancy has worked in a variety of functions (R&D, Commercial, Worldwide Business Development) in the US and UK, including 15 years leading the global Transactions team in Business Development at GSK. Since 2009, she has held various positions in public and privately funded healthcare companies and advised Venture Capital Health groups in US and Europe. This experience has provided her with a broad oversight and understanding of the industry. Annette currently serves as the Chair of the Compensation Nomination and Governance Committee at ObsEva SA, is a non-Executive Director on the Board of the Swedish Public Company, Sobi and is Chairperson of the Board of two other Companies; the public French company Lysogene SA and a privately held French company Enyo SA.
Ms. Clancy holds a BSc (Hons) Pharmacology from Bath University (UK) and a series of American Management Association diplomas (finance/marketing).